WEST HARRISON, NY / ACCESSWIRE / September 1, 2015 / The continuing progress of CEL-SCI Corporation (NYSE MKT: CVM), arguably the most undervalued Phase III biotech company, is profiled in the August 27th issue of Flaherty Financial Newsletter #50. 2017 is the expected date for the overall survival readout of this very important $50 million, 24 countries global Phase III trial for advanced primary head and neck cancer. This trial seeks to prove something novel and imminently logical. Boosting the immune system before surgery, radiation and chemotherapy, while it is still intact, should yield great benefit for these newly diagnosed cancer patients. This has never been done and a success should send CEL-SCI stock soaring.

Taking a unique approach, CEL-SCI wants to strengthen the immune system of newly identified cancer patients with its three week Multikine regime during the brief four week window before current global standard of care mandates that surgery plus radiation and /or chemotherapy commence. It is the largest global trial for head and neck cancer patients in history. In contrast, other peer cancer immunotherapy companies, which require much longer treatment times, aim to boost the immune system after the tumor has recurred, when the immune system may have been debilitated by the toxicity from radiation and chemotherapy.

After a very slow start to the Phase III study under a prior Clinical Research Organization, CEL-SCI is enrolling about one newly diagnosed cancer patient a day. The study is progressing well and is in its end stage, but its stock is selling near its all- time low. Three upcoming events, all in the very near future, could put CEL-SCI back on Wall Street's radar screen and result in an upward reset of its share price. One is CEL-SCI's $50 million arbitration suit against CEL-SCI's former clinical research organization is scheduled to start this fall. Second is full enrollment of 880 cancer patients in their Multikine regimen Phase III trial should be completed by March 31, 2016. Third would be human data from a separate Multikine anal warts Phase I study in co-infected HIV/HPV patients. This disease is a rarely discussed but very important unmet need for the HIV patients whose compromised immune system cannot clear the HPV.

Success in this global Phase III trial could give Multikine the potential to become the fourth standard of care for cancer, joining surgery, chemo and radiation.

Our complete in depth sponsored CEL-SCI Corporation profile can be found archived on our Flaherty Financial News website at http://www.flahertyfinancialnews.com/.

Direct Server Link to The Report - With The Modern Social Share Buttons:

http://campaign.r20.constantcontact.com/render?ca=d94d3a93-506b-430f-b62d-44394528f602&c=ba013f80-1d50-11e3-bf73-d4ae52754007&ch=ba97b320-1d50-11e3-bf9e-d4ae52754007

About Flaherty Financial News Inc.

Flaherty Financial News Inc. ("FFN") is the publisher of totally-electronic coverage of interesting public companies. FFN was launched in 2007 by the "legendary financial editor" Bob Flaherty, Editor and Chairman of Flaherty Financial News Inc., and his son Brian, President and Publisher. While previously serving as Chairman and Editor of Equities Magazine for twenty-five years and also Editor-in-Chief of Equities Special Situations, Bob had one of the most consistent and highest ranked long-run performance records measured by Hulbert Financial Digest. He is also an award-winning retired Senior Editor of Forbes Magazine, where he wrote 33 cover stories, two shy of the all-time Forbes record. He was also Chairman of The Over-The-Counter Securities Fund. Bob Flaherty is a Magna Cum Laude graduate of Harvard College in economics and also has an MBA with a Distinction in Finance from Harvard Business School. A former president of the New York Financial Writers' Association, Bob is a co-founder of their annual student scholarship program and their annual award for significant long-term achievement in financial journalism.

About CEL-SCI Corporation.

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy Multikine (Leukocyte Interleukin, injection) is currently being studied in a pivotal Phase III clinical trial as a potential neo-adjuvant treatment for patients with squamous cell carcinoma of the head and neck. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with the Multikine treatment regimen plus the current standard of care as compared to subjects treated with the current standard of care only is satisfied, the study results will be used to support applications that the Company plans to submit to regulatory agencies in order to seek commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multkine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase I trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase I trial in conjunction with the U.S. Naval Medical Center, San Diego, under a CRADA (Cooperative Research and Development Agreement).

CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis. The Company has operations in Vienna, Virginia and in and near Baltimore, Maryland.

Forward-Looking Statements:

This news release contains "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of l995) regarding the Flaherty Financial News Newsletter profile on CEL-SCI Corporation and its future business plans. These statements involve known and unknown risks and uncertainties, which may cause actual results and future achievements to be materially different than those implied by these forward-looking statements. Flaherty Financial News Inc. and CEL-SCI Corporation have and undertake no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in their expectations of future events. Our full disclaimer and safe harbor statement appears in our Flaherty Financial News Newsletter.

CONTACT:

Flaherty Financial News Inc.
Robert J. Flaherty, Editor and Chairman
Phone: (914) 831-1151
http://www.flahertyfinancialnews.com

SOURCE: Flaherty Financial News Inc.